Catalyst Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Catalyst Pharmaceuticals, Inc. filed an amendment to its 2025 Annual Report to include required governance and executive compensation disclosures.
NASDAQ
Catalyst Pharmaceuticals reported significant revenue and net income growth in its 2025 annual report, primarily fueled by the successful commercialization of AGAMREE and continued FIRDAPSE sales, despite generic competition for FYCOMPA.
NASDAQ
10-K: Catalyst Pharmaceuticals Reports Strong Financial Performance in 2024, Navigates Patent Challenges
Catalyst Pharmaceuticals' 2024 10-K filing highlights increased revenue driven by FIRDAPSE and AGAMREE, while addressing ongoing patent litigation and strategic portfolio expansion.
NASDAQ
Catalyst Pharmaceuticals has detailed its executive severance and change in control plan, outlining benefits for senior management upon termination or change in control.